AN ANTIEPILEPTIC add-on treatment shown to be effective without the need to titrate for tolerability, is now PBS funded.
Briviact (brivaracetam) from UCB is an add-on therapy for the treatment of partial-onset seizures (POS) without secondary generalisation in patients from 16 years of age with epilepsy.
Available in both tablets and oral solution, Briviact is an Authority Required (streamlined) PBS listed product although the injectable form is not funded on the PBS.
See the PI at ucbpharma.com.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 May 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 May 18
